PCVX Vaxcyte, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1649094 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-74.8%
TTM EPS YoY-66.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-42.7%
ROA-37.3%
ROIC (approx.)-39.1%
Asset turnover—
Leverage & solvency
Liabilities / assets16.7%
Debt / equity0.00x
Current ratio4.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $794.31M | $476.64M | $332.34M | $169.45M | $78.41M |
| SG&A expense | $129.37M | $92.90M | $60.70M | $39.81M | $25.26M |
| Operating income | -$923.67M | -$569.55M | -$468.04M | -$232.26M | -$103.67M |
| Interest expense | — | $0 | $0 | $2,000 | $7,000 |
| Income tax | $0 | $0 | $0 | — | — |
| Net income | -$766.63M | -$463.93M | -$402.27M | -$223.49M | -$100.08M |
| EBITDA | -$907.28M | -$562.54M | -$464.88M | -$229.42M | -$101.87M |
| EPS (basic) | -5.63 | -3.80 | -4.14 | -3.44 | -1.93 |
| EPS (diluted) | -5.63 | -3.80 | -4.14 | -3.44 | -1.93 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 136.09M | 122.00M | 97.16M | 64.88M | 51.92M |
| Balance sheet | |||||
| Cash & equivalents | $173.96M | $389.19M | $397.45M | $835.53M | $69.86M |
| Short-term investments | $1.39B | $1.36B | $682.78M | $96.72M | $176.99M |
| Current assets | $1.63B | $1.79B | $1.10B | $942.55M | $256.35M |
| PP&E, net | $257.37M | $198.04M | $79.63M | $10.36M | $7.95M |
| Total assets | $3.00B | $3.51B | $1.41B | $1.01B | $324.34M |
| Current liabilities | $205.75M | $140.18M | $145.34M | $40.52M | $28.72M |
| Total liabilities | $317.21M | $205.50M | $167.45M | $52.56M | $40.32M |
| Shareholders' equity | $2.69B | $3.31B | $1.24B | $953.61M | $284.02M |
| Shares outstanding | 131.06M | 124.89M | 95.36M | 79.47M | 53.03M |
| Cash flow statement | |||||
| Operating cash flow | -$655.58M | -$452.63M | -$296.79M | -$170.60M | -$121.39M |
| Capital expenditure | $13.71M | $22.43M | $16.06M | $5.84M | $6.55M |
| Free cash flow | -$669.29M | -$475.05M | -$312.85M | -$176.44M | -$127.95M |
| Investing cash flow | $437.35M | -$2.01B | -$773.31M | $74.58M | -$212.31M |
| Financing cash flow | $2.01M | $2.45B | $639.81M | $861.55M | $17.80M |
| Depreciation & amortization | $16.40M | $7.00M | $3.16M | $2.83M | $1.80M |
| Stock-based compensation | $138.84M | $84.82M | $48.76M | $23.65M | $10.73M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.